Last reviewed · How we verify

NCT03909607

Nebulized Sub-dissociative Dose Ketamine for Treating Pain

Completed Phase 4 Results posted Last updated 15 June 2022
What this trial tests

Phase 4 trial testing Ketamine 0.75 mg/kg in Pain in 120 participants. Completed in 30 June 2021.

Timeline
16 April 2019
Primary endpoint
30 October 2020
30 June 2021

Quick facts

Lead sponsorAntonios Likourezos
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment120
Start date16 April 2019
Primary completion30 October 2020
Estimated completion30 June 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Antonios Likourezos — full company profile →

Who can join

Adults 18 to 120, any sex, with Pain. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change in Pain Scores From Baseline to 30 Minutes Primary · 30 minutes

Patients will be assessed via an 11 point Likert numeric rating scale at time medication is given (baseline) and 30 minutes later. The difference in pain scores will be assessed between the 3 groups. The numeric rating scale range is from 0 to 10 with 0 being no pain and 10 being very severe pain.

GroupValue95% CI
SDK 0.75 mg/kg4.0± 1.9
SDK 1.0 mg/kg4.2± 2.1
SDK 1.5 mg/kg4.1± 1.9

Adverse events — posted to ClinicalTrials.gov

Time frame: 120 minutes. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

SDK 0.75 mg/kg
Serious: 0/40 (0%)
Deaths: 0/40
SDK 1.0 mg/kg
Serious: 0/40 (0%)
Deaths: 0/40
SDK 1.5 mg/kg
Serious: 0/40 (0%)
Deaths: 0/40
Other adverse events (1 terms — click to expand)

ReactionSystemSDK 0.75 mg/kgSDK 1.0 mg/kgSDK 1.5 mg/kg
DizzinesNervous system disorders

Data from ClinicalTrials.gov NCT03909607 adverse events section.

Sponsor's own description

The investigators previous research study comparing the efficacy of intravenous ketamine to morphine showed ketamine to provide equivalent relief of moderate to severe acute pain in emergency department patients. A second study by the investigators showed that increasing the time of administration of the ketamine, from a push injection to a drip infusion, will minimize the adverse effects experienced by recipients of ketamine. The investigators now aim to see if nebulized subdissociative-dose ketamine administered as a single agent in a dose of 1.5 mg/kg via Breath-Actuated Nebulizers (BAN) over 5-15 minutes will provide a better pain relief in comparison to 1 mg/kg and 0.75 mg/kg doses or if the lower doses are equally as effective.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Pain

Currently open trials in the same condition.

Other Antonios Likourezos trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03909607.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing